Spectral MD takes steps toward Rosecliff Acquisition Corp merger

Spectral MD Holdings' general counsel Vince Capone joins Steve Darling on Proactive to provide insights into the latest developments at the company.

Capone highlighted the significance of Rosecliff Acquisition Corp's filing of Form 424, a crucial step in Spectral MD's ongoing journey. This filing is triggered by the effectiveness of the RS-4 with Rosecliff, signifying an upcoming shareholder meeting to approve the transaction.

The merger aims to reshape Spectral MD into a holding company under Rosecliff, adopting the new name "Spectral AI." This transformation also involves a NASDAQ ticker change from "CLF" to "MD AI."

Capone underlined a significant milestone – the successful clearance of the SEC examiner's review, which is pivotal for the transaction. He noted the accelerated timeline for this process compared to the typical three to four months, indicating the company's agile approach.

The timeline for further progress is set for September 8, targeting the NASDAQ listing, and the company's exit from other markets.

With shareholder meetings for both Spectral MD and Rosecliff scheduled for August 31 and September 6 respectively, the rapid pace of developments is evident.

Capone expressed his enthusiasm for the exciting journey ahead, recognizing the dedicated efforts of the team. The transformation promises to be a substantial stride for Spectral MD, and the interview concluded with anticipations for the upcoming listing and more updates.

Contact Details

Proactive USA

+1 604-688-8158

na-editorial@proactiveinvestors.com